Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Simone Ferretti, Chiara Mercinelli, Laura Marandino, Giulio Litterio, Michele Marchioni & Luigi Schips. (2023) Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs. Research and Reports in Urology 15, pages 243-259.
Read now
Read now
Michele Marchioni, Laura Marandino, Daniele Amparore, Francesco Berardinelli, Marco Mascitti, Matteo Ferro, Riccardo Campi & Luigi Schips. (2022) Factors influencing survival in metastatic castration-resistant prostate cancer therapy. Expert Review of Anticancer Therapy 22:10, pages 1061-1079.
Read now
Read now
Articles from other publishers (14)
Oliver Snow, Nada Lallous, Martin Ester & Artem Cherkasov. (2020) Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies. International Journal of Molecular Sciences 21:16, pages 5847.
Crossref
Crossref
Yin-Gi Jang, Ryu-Eun Go, Kyung-A Hwang & Kyung-Chul Choi. (2019) Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway. The Journal of Steroid Biochemistry and Molecular Biology 192, pages 105406.
Crossref
Crossref
Sumanta K. Pal, Miaoling He, Lin Chen, Lixin Yang, Raju Pillai, Przemyslaw Twardowski, JoAnn Hsu, Marcin Kortylewski & Jeremy O. Jones. (2018) Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Urologic Oncology: Seminars and Original Investigations 36:4, pages 162.e1-162.e6.
Crossref
Crossref
Nada Lallous, Stanislav V. Volik, Shannon Awrey, Eric Leblanc, Ronnie Tse, Josef Murillo, Kriti Singh, Arun A. Azad, Alexander W. Wyatt, Stephane LeBihan, Kim N. Chi, Martin E. Gleave, Paul S. Rennie, Colin C. Collins & Artem Cherkasov. (2016) Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology 17:1.
Crossref
Crossref
Nada Lallous, Eric Leblanc, Ravi S.N. Munuganti, Mohamed D.H. Hassona, Nader Al Nakouzi, Shannon Awrey, Helene Morin, Mani Roshan-Moniri, Kriti Singh, Sam Lawn, Takeshi Yamazaki, Hans H. Adomat, Christophe Andre, Mads Daugaard, Robert N. Young, Emma S. Tomlinson Guns, Paul S. Rennie & Artem Cherkasov. (2016) Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Molecular Cancer Therapeutics 15:12, pages 2936-2945.
Crossref
Crossref
Mark C. Markowski, Kevin D. Frick, James R. Eshleman, Jun Luo & Emmanuel S. Antonarakis. (2016) Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. The Prostate 76:16, pages 1484-1490.
Crossref
Crossref
L Wang, G Song, X Chang, W Tan, J Pan, X Zhu, Z Liu, M Qi, J Yu & B Han. (2014) The role of TXNDC5 in castration-resistant prostate cancer—involvement of androgen receptor signaling pathway. Oncogene 34:36, pages 4735-4745.
Crossref
Crossref
Bernard Robaire & Barry T. Hinton. 2015. Knobil and Neill's Physiology of Reproduction. Knobil and Neill's Physiology of Reproduction
691
771
.
Tristan M. Sissung, Douglas K. Price, Marzia Del Re, Ariel M. Ley, Elisa Giovannetti, William D. Figg & Romano Danesi. (2014) Genetic variation: effect on prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846:2, pages 446-456.
Crossref
Crossref
Jill Gallaher, Leah M. Cook, Shilpa Gupta, Arturo Araujo, Jasreman Dhillon, Jong Y. Park, Jacob G. Scott, Julio Pow-Sang, David Basanta & Conor C. Lynch. (2014) Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clinical & Experimental Metastasis 31:8, pages 991-999.
Crossref
Crossref
Lei Wang, Wenfang Li, Muqing Lin, Monika Garcia, David Mulholland, Michael Lilly & Manuela Martins-Green. (2014) Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis 35:10, pages 2321-2330.
Crossref
Crossref
Fable Zustovich & Francesca Fabiani. (2014) Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Critical Reviews in Oncology/Hematology 91:2, pages 197-209.
Crossref
Crossref
Lunawati L. Bennett & April Ingason. (2014) Enzalutamide (Xtandi) for Patients With Metastatic, Resistant Prostate Cancer. Annals of Pharmacotherapy 48:4, pages 530-537.
Crossref
Crossref
Nada Lallous, Kush Dalal, Artem Cherkasov & Paul Rennie. (2013) Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences 14:6, pages 12496-12519.
Crossref
Crossref